Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larisa Geskin

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Skin Therapy Letter|May 20, 2011
Therapeutic advances in cutaneous T-cell lymphomaOleg E Akilov, Larisa Geskin
The Journal of Dermatological Treatment|December 2, 2017
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphomaLarisa Geskin, Daniel C Malone
The Oncologist|July 19, 2018
A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and ManagementAdriana T Lopez, Larisa Geskin
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studiesMadeleine Duvic, Larisa Geskin, H Miles Prince
American Journal of Clinical Dermatology|September 3, 2018
Current Status of HDAC Inhibitors in Cutaneous T-cell LymphomaAdriana T Lopez, Susan Bates, Larisa Geskin
Clinical Journal of Oncology Nursing|October 2, 2012
Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphomaSue McCann, Oleg E Akilov, Larisa Geskin
Oncology (Williston Park, N.Y.)|April 24, 2018
Secondary Prevention Strategies for Nonmelanoma Skin CancerAdriana T Lopez, Richard D Carvajal, Larisa Geskin
Experimental Dermatology|November 30, 2016
The biomarker landscape in mycosis fungoides and Sézary syndromeBrittany Dulmage, Larisa Geskin, Joan Guitart, et al.
The British Journal of Dermatology|February 22, 2022
Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sézary cell phenotypeTony T Jiang, Oleg Kruglov, Larisa Geskin, et al.
International Journal of Dermatology|April 10, 2018
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitorsAdriana T Lopez, Trisha Khanna, Nina Antonov, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Skin Therapy Letter|May 20, 2011
Therapeutic advances in cutaneous T-cell lymphomaOleg E Akilov, Larisa Geskin
The Journal of Dermatological Treatment|December 2, 2017
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphomaLarisa Geskin, Daniel C Malone
The Oncologist|July 19, 2018
A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and ManagementAdriana T Lopez, Larisa Geskin
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studiesMadeleine Duvic, Larisa Geskin, H Miles Prince
American Journal of Clinical Dermatology|September 3, 2018
Current Status of HDAC Inhibitors in Cutaneous T-cell LymphomaAdriana T Lopez, Susan Bates, Larisa Geskin
Clinical Journal of Oncology Nursing|October 2, 2012
Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphomaSue McCann, Oleg E Akilov, Larisa Geskin
Oncology (Williston Park, N.Y.)|April 24, 2018
Secondary Prevention Strategies for Nonmelanoma Skin CancerAdriana T Lopez, Richard D Carvajal, Larisa Geskin
Experimental Dermatology|November 30, 2016
The biomarker landscape in mycosis fungoides and Sézary syndromeBrittany Dulmage, Larisa Geskin, Joan Guitart, et al.
The British Journal of Dermatology|February 22, 2022
Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sézary cell phenotypeTony T Jiang, Oleg Kruglov, Larisa Geskin, et al.
International Journal of Dermatology|April 10, 2018
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitorsAdriana T Lopez, Trisha Khanna, Nina Antonov, et al.
Pageof 4